Brief: Turn Therapeutics Reports Interim Analysis Findings And Adaptive Optimization Strategy From Phase 2 GX-03 Trial In Moderate-To-Severe Atopic Dermatitis
01/06/2026 13:41
BRIEF-Turn Therapeutics Reports Interim Analysis Findings And Adaptive Optimization Strategy From Phase 2 GX-03 Trial In Moderate-To-Severe Atopic Dermatitis June 1 (Reuters) - Turn Therapeutics Inc TTRX.O:
TURN THERAPEUTICS REPORTS INTERIM ANALYSIS FINDINGS AND ADAPTIVE OPTIMIZATION STRATEGY FROM PHASE 2 GX-03 TRIAL IN MODERATE-TO-SEVERE ATOPIC DERMATITIS
TURN THERAPEUTICS - NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS OR DISCONTINUATIONS REPORTED IN INTERIM ANALYSIS
TURN THERAPEUTICS - INTERIM ANALYSIS LEADS TO TRIAL ENROLLMENT AND ENDPOINT REFINEMENT
Source text: ID:nBw6gzQhJa
Further company coverage: TTRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Turn Therapeutics
See all newsTurn Therapeutics Q2 net loss per share widens on higher R&D costs
Turn Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview
Turn Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Turn Therapeutics Reports Interim Analysis Findings And Adaptive Optimization Strategy From Phase 2 GX-03 Trial In Moderate-To-Severe Atopic Dermatitis
Brief: Turn Therapeutics Reports First Quarter 2026 Financial Results